"Determination of mOBD is being made by the Cohort Review Committee (CRC) review andrequires successive dosing within cohorts of at least 3 patients each. The CRC met today toreview safety and tolerability data after the last patient in the first cohort completed 30 days oftreatment. The CRC confirmed the dose in the first cohort as safe and tolerable and hasapproved enrolment of patients to the next higher dose level. The highest safe dose level withthe best immune response becomes the mOBD."
I think this may be a cut and paste error, as the announcement to up dosage from 1st cohort to 2nd cohort came on 21 January - https://hotcopper.com.au/threads/ann-imugene-dose-escalates-in-pd1-vaxx-phase-1-clinical-trial.5865305/
and the announcment for second cohort dosing came on 12 February
https://hotcopper.com.au/threads/ann-imugene-commences-cohort-2-dosing-in-phase-1-pd1-vaxx-trial.5902048/
Ann: Half Yearly Report and Accounts, page-2
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $505.0M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.8¢ | $1.427M | 20.55M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 57517 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 667419 | 9 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.000 ( 0.29 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.1¢ | 6.8¢ | 7149293 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| IMU (ASX) Chart |